Your Feed

Filter by
See content from
Back to the latest
Thumbnail for Outcomes in High-Risk Subgroups After Ibrutinib and Venetoclax for CLL | Ryan Jacobs, MD | EHA 2024
Playlist: EHA 2024

Outcomes in High-Risk Subgroups After Ibrutinib and Venetoclax for CLL | Ryan Jacobs, MD | EHA 2024

Video details & playlist